The Conversation (0)
Q1 is now over, and to mark the occasion, Life Science Investing News has assembled the articles that got the most traffic during the period. Unsurprisingly, readers were most interested in hearing about trends for 2015, though stock picks were also a key topic.
Q1 is now over, and to mark the occasion, Life Science Investing News has assembled the articles that got the most traffic during the period.
Unsurprisingly, readers were most interested in hearing about trends for 2015, though stock picks were also a key topic. Read on for overviews of those articles and more.
1. JPMorgan’s 2015 Life Science Stock Picks
At the tail end of 2014, JPMorgan Chase & Co. (NYSE:JPM) released a report containing a selection of stock picks from a variety of life science sectors. Life Science Investing News picked a few of the firm’s top choices to profile, outlining what exactly makes them interesting.
Here’s a few of the companies listed by JPMorgan: BioMarin Pharmaceutical (NASDAQ:BMRN), Illumina (NASDAQ:ILMN), Spectranetics (NASDAQ:SPNC), Medtronic (NYSE:MDT) and Valeant Pharmaceuticals International (TSX:VRX,NYSE:VRX). Those interested in the space might want to check up on them now to see how they’re doing. Click here to read the full article.
2. Life Science Outlook 2015: Get Set for Innovation, Idea Sharing and Increased Funding
Investors are always looking to identify what trends are on the horizon, so it’s no surprise that Life Science Investing News’ 2015 outlook piece was one of the most popular articles this past quarter.
The article outlines three trends that Forbes anticipated rocking the sector in 2015, including widespread innovation, more money for research and development and entrepreneurs stepping up to take the lead. Click here to read the full article.
3. 2015 TSX Venture 50: Life Science Companies on the List
The TSX Venture Exchange’s much-anticipated TSX Venture 50 list was released in February. Companies were chosen using an equal weighting of four measures: market cap growth, share price appreciation, trading volume and analyst coverage; a number of other factors were taken into account as well.
Two life science companies made the list: Patient Home Monitoring (TSXV:PHM) and Theralase Technologies (TSXV:TLT). The former is focused on acquiring small, privately held companies servicing chronically ill patients hampered by diseases caused mainly by old age and obesity, while the latter is involved in designing, developing and manufacturing “super-pulsed, cold laser technology” that can be used for a wide range of human, companion animal and equine applications. Click here to read the full article.
4. Breaking Down the Diabetes Testing Market
Unlike many diseases, most people have likely heard of diabetes. However, not everyone is aware of just what it entails. This article looks at companies in the life science arena that are looking to help people with different aspects of the disease, mentioning firms like Miraculins (TSXV:MOM), Medtronic (NYSE:MDT), Bayer (ETR:BAYN), M Pharmaceutical (CSE:MQ) and Dexcom (NASDAQ:DXCM). Click here to read the full article.
5. biOasis Delivers siRNA to Animal Brain with Therapeutic Effect
Rounding out the list is a piece on biOasis Technologies (TSXV:BTI), a company that’s focused on the delivery of therapeutics across the blood-brain barrier and into the brain tissue.
The company made headlines in March when it announced the results of an animal ischemic stroke model. Their significance is a little tough to understand without some background information on the company and its work, and this article breaks down exactly those concepts. Click here to read the full article.
Securities Disclosure: I, Charlotte McLeod, hold no direct investment interest in any company mentioned in this article.
Related reading:
5 Top Silver Stories for Q1 2015
5 Top Gold Stories for Q1 2015
5 Top Copper Stories for Q1 2015
5 Top Uranium Stories for Q1 2015